Key Highlights

  • Recce Pharmaceuticals Ltd (ASX:RCE) shares were priced at $0.335 on 20 October 2026, a gain of 15.52% in the session.
  • A data set of 75 patients has been submitted to the independent Data Monitoring Committee, which is expected to meet as soon as mid-November 2026.
  • The Phase 3 trial in Indonesia has 90 patients enrolled, with an enrolment rate of 4.5 patients per week.

During the Trading session on 20 October 2026, Recce Pharmaceuticals Ltd (ASX:RCE) shares were priced at $0.335, a gain of 15.52%. The company also released an announcement on 20 October 2026. It said an independent Data Monitoring Committee (DMC) will review unblinded data from the company's Phase 3 diabetic foot infection trial in Indonesia, and set out the process, the possible recommendations and the expected timing.

Company Background

Recce Pharmaceuticals Ltd, listed on the ASX and the Frankfurt Stock Exchange (FSE:R9Q), is developing what it calls a new class of synthetic anti-infectives aimed at antibiotic-resistant superbugs. Its pipeline includes three patented, broad-spectrum synthetic polymer anti-infectives: RECCE 327 (R327), an intravenous and topical therapy being developed for serious and potentially life-threatening infections caused by Gram-positive and Gram-negative bacteria, including superbug forms; RECCE 435 (R435), an orally administered therapy for bacterial infections; and RECCE 529 (R529) for viral infections.

The company says the World Health Organization added all three to its list of antibacterial products in clinical development for priority pathogens. The US FDA granted R327 Qualified Infectious Disease Product designation under the GAIN Act, which provides Fast Track Designation and 10 years of market exclusivity after approval. Recce says it wholly owns the automated Manufacturing that supports its current clinical trials.

The Phase 3 Trial and Data Monitoring Process

The study is a pivotal, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of RECCE 327 Gel (R327G) in diabetic foot infections (DFI) in Indonesia. Ninety patients are currently enrolled, at a rate of 4.5 patients per week. A data set of 75 patients has now been formally submitted to the DMC, which will unblind the data, meaning it will create separate data sets for patients who received R327G and those who received placebo gel.

The company explained that independent oversight by a data monitoring committee is a component of any pivotal trial run under Good Clinical Practice. The committee periodically reviews accumulating efficacy and safety outcomes and makes recommendations on how the study should proceed. While the DMC conducts its ad-hoc review, the company, clinical investigators and patients will remain fully blinded to treatment groups to protect the scientific integrity of the trial. Patient recruitment and dosing continue during the process.

Blinded Data Review and Possible Recommendations

Before the DMC submission, the company said Australian and international infectious disease specialists, clinical investigators and biostatistical experts reviewed the blinded data after patient follow-up was completed. Recce said the review indicated efficacy across the study population, with a high proportion of patients experiencing either resolution or improvement of infection, and that blinded safety data continued to indicate R327G is safe and well tolerated.

After its meeting, the DMC will submit its findings and recommendations to the company. Recce said, in line with standard clinical protocols, these may include advising the company to progress towards regulatory submission and potential product registration if supported by the safety and efficacy data, continuing the trial unchanged, amending the protocol (for example sample sizes, dosing schedules or patient selection criteria), or pausing or halting the trial due to safety concerns or clear futility.

Sector Backdrop

Antimicrobial resistance is a recognised global health concern. In an October 2025 report on the antibacterial pipeline, the World Health Organization counted 90 antibacterials in clinical development, down from 97 in 2023. Of those, 15 were classed as innovative and only 5 were active against at least one pathogen on the WHO's critical priority list.

Risks Shareholders Should Weigh

Clinical-stage Drug Development carries inherent uncertainty. The company noted that the DMC may recommend continuing the trial unchanged, amending the protocol, or pausing or halting the study due to safety concerns or clear futility, in addition to progressing towards a regulatory submission. The outcome of the unblinded review is not known to the company, and the announcement describes the blinded data review rather than final trial results.

Regulatory approval is not assured for any product candidate, and a regulatory submission, if one occurs, would be subject to assessment by the relevant authorities. The DMC meeting date is described as expected as soon as mid-November 2026. Phase 3 trials also depend on continued patient recruitment, and clinical-stage companies generally rely on available funding to complete trials, which the announcement does not discuss.

What's Next

The DMC will unblind and review the efficacy and safety data from the 75-patient data set and prepare recommendations. The committee's meeting is expected as soon as mid-November 2026, and its recommendations will be available to the company after the meeting concludes.

Recce said it will provide a market update once it has received and evaluated the DMC's formal recommendations, in accordance with its continuous disclosure obligations. Patient recruitment and dosing will continue in the meantime, and the company, investigators and patients will remain blinded to treatment allocation.